Summary
Katie Dawson is a hypothyroidism sufferer and needs specific treatment to keep herself well. In this opinion piece, she explains why she resorted to sourcing her own medication from abroad.
Katie builds on the safety concerns raised in a recent blog by Mary Saunders, and calls for an individualised care approach to hypothyroidism, so that everyone can access the treatment they need.
Content
My less common hypothyroidism
When I first started medication for hypothyroidism, I was put on T4, or levothyroxine, which is commonly used in the UK. Unfortunately, it had no discernible effect on my symptoms. Searching for alternatives, with the help of a private doctor, I found a medication from the US that combined two hormones (T4 and T3 and others). I responded well to this treatment.
Through genetic testing which I privately sourced, I came to understand that my response was due to faulty genes for the enzymes that convert T4 (storage) to T3 (active).
I need T3 in my treatment, as I can’t produce it myself.
Barriers to treatment
My GP had requested the specific lab tests that I needed (including T3 and antibodies), in order to manage this effectively, but the lab couldn’t accommodate this. T4 and Thyroid-Stimulating Hormone was therefore the only thing I was able to obtain through my GP.
There seemed little point in fighting for what they were unable or unwilling to offer.
I joined some specialist thyroid self-help groups, digested scientific papers and developed a deeper understanding of hypothyroidism.
The costs of the private consultations and obtaining the US treatment were rising to unsustainable levels. I needed to do something different, to manage the financial impact while also getting the treatment I need to feel well.
A decision I shouldn’t have to make
I got my own blood tests done, researched what they meant for my treatment, and decided to directly source the medicine from overseas pharmacies.
I initially continued with the US treatment as advised by the doctor, but it shot up in price and there were a number of quality problems with the cheaper alternative brands. Maintaining energy to function and hold down my job became tricky.
This resulted in me switching to synthetic T3 alone, in the hope of having a more consistent product and this is where I have remained .
Self-treatment was the only economical way to do it, since despite having an exemption certificate for essential life-saving medicines like these (so they should be free) the cost of T3 in the UK without NHS support was huge. That is not the case abroad, where T4 and T3 are often similar in price and far cheaper.
The patient safety concern
Many patients like me are sourcing their medicines from abroad in order to continue to have a normal family life and hold down their jobs. There are inherent risks in doing this because they have to take on trust that the sources are legitimate and the products sold authentic, since they can’t vet them personally.
They try to find reputable sources from overseas pharmacies but there is always the risk of someone falling prey to a scammer offering unsafe or just ineffective medicines.
Self-sourcing absolves the NHS of providing the treatment that individuals need and pushes the risk to patients. They ration T3 due to the cost.
There is also a risk the rules that allow the importation of medicine for personal use are revoked. This is a major concern since patients like me can’t rely on the NHS to provide the treatment that they need.
We could be left in a far more difficult situation of being untreated and unable to self-source. In fact, many fellow suffers have begged me not to raise this issue for fear that their only way of obtaining effective treatment is removed.
Individualised care is overdue
There is currently no individualisation of care in hypothyroidism. Unless doctors are prepared to treat the patient in front of them and take account of their symptoms, the treatment of hypothyroidism is ineffective for a significant minority of patients (thought to be 10-20% of over £2m hypothyroid UK patients).[1]
[1] Bianco AC. Emerging Therapies in Hypothyroidism. Annu Rev Med. 2024 Jan 29;75:307-319. doi: 10.1146/annurev-med-060622-101007. Epub 2023 Sep 22.
Share your experience
Have you been affected by any of the issues raised by Katie? Or perhaps you have experienced other medication supply issues as a patient, carer or healthcare professional? Please comment below to share your thoughts with Patient Safety Learning (you'll need to sign up first for free).
Further information
Thyroid UK - https://thyroiduk.org
NHS England: “Hypothyroidism is caused by deficiency of thyroid hormones, which are essential for normal growth, development and metabolism. It can usually be treated effectively with levothyroxine (L-T4) alone. However, a small proportion of patients treated with levothyroxine continue to have symptoms despite adequate biochemical correction. For these patients, oral liothyronine (triiodothyronine; L-T3) may be appropriate.” (source: NHS England » Liothyronine – advice for prescribers)
National Institute of Clinical Excellence - NICE guideline NG145 - Thyroid disease: assessment and management
9 Comments
Recommended Comments
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now